title: First line targeted therapies in breast cancer: focus on bevacizumab.
abstract: The heterogeneity of metastatic breast cancer mandates the need to select therapies taking into account tumor and patient characteristics. Chemotherapy is indicated in the palliative setting especially when the disease is unresponsive to hormonal therapy or is hormone-receptor negative. The main chemotherapeutic agents are anthracyclines, taxanes, and capecitabine. The knowledge of the effects of currently approved agents and of the biology of breast cancer have paved the way for the evaluation of new treatment options, among which are anti-angiogenic agents. Angiogenesis inhibition has resulted in clinically significant improvements in the outcome of a variety of malignancies, including breast cancer. Bevacizumab, a monoclonal antibody anti-vascular endothelial growth factor (VEGF), is the most extensively studied anti-angiogenic compound. According to the results of a phase III trial in patients with untreated metastatic breast cancer, bevacizumab increases both objective response rate and median progression-free survival when combined with standard chemotherapy vs chemotherapy alone. The combination of anti-angiogenic drugs and other biologic agents is also being explored in an attempt to improve efficacy.
authors.affiliation: Istituto Nazionale Tumori "Fondazione G. Pascale" Via M. Semmola, 80131, Napoli, Italy.
authors.forename: Amalia
authors.initials: A
authors.lastname: Milano
authors.forename: Gugliemo
authors.initials: G
authors.lastname: Nasti
authors.forename: Rosario Vincenzo
authors.initials: RV
authors.lastname: Iaffaioli
authors.forename: Francesco
authors.initials: F
authors.lastname: Caponigro
references.citation: Cancer Res. 2006 Feb 1;66(3):1630-9
references.pmid: 16452222
references.citation: Cancer Res. 2001 Jul 1;61(13):5090-101
references.pmid: 11431346
references.citation: Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11
references.pmid: 10198732
references.citation: J Natl Cancer Inst. 2001 Feb 21;93(4):309-14
references.pmid: 11181778
references.citation: J Clin Invest. 1999 Oct;104(7):913-23
references.pmid: 10510332
references.citation: Endocr Rev. 1997 Feb;18(1):4-25
references.pmid: 9034784
references.citation: N Engl J Med. 1995 Dec 28;333(26):1757-63
references.pmid: 7491141
references.citation: Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24
references.pmid: 14613032
references.citation: Cancer Res. 2000 Oct 15;60(20):5879-86
references.pmid: 11059786
references.citation: Hum Pathol. 1995 Jan;26(1):86-91
references.pmid: 7821921
references.citation: Nature. 1993 Apr 29;362(6423):841-4
references.pmid: 7683111
references.citation: J Clin Oncol. 2006 Feb 10;24(5):769-77
references.pmid: 16391297
references.citation: Ann Oncol. 2001 Sep;12(9):1247-54
references.pmid: 11697835
references.citation: J Biol Chem. 1997 Sep 5;272(36):22642-7
references.pmid: 9278421
references.citation: J Natl Cancer Inst. 1997 Jan 15;89(2):139-47
references.pmid: 8998183
references.citation: Cancer Res. 2001 Jul 15;61(14):5407-14
references.pmid: 11454684
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: Cancer Res. 1996 May 15;56(10):2299-301
references.pmid: 8625303
references.citation: J Clin Oncol. 2003 Feb 15;21(4):588-92
references.pmid: 12586793
references.citation: Clin Cancer Res. 2006 May 15;12(10):3124-9
references.pmid: 16707611
references.citation: J Cancer Res Clin Oncol. 1998;124(9):523-5
references.pmid: 9808428
references.citation: Mol Cell Biol. 2001 Jun;21(12):3995-4004
references.pmid: 11359907
references.citation: J Clin Oncol. 2001 Feb 1;19(3):843-50
references.pmid: 11157038
references.citation: J Am Soc Nephrol. 1998 Nov;9(11):1998-2004
references.pmid: 9808085
references.citation: Br J Cancer. 2001 May 18;84(10):1322-9
references.pmid: 11355942
references.citation: J Clin Oncol. 2005 Mar 10;23(8):1782-90
references.pmid: 15755986
references.citation: Cancer Res. 2000 Jun 1;60(11):2926-35
references.pmid: 10850439
references.citation: Cancer Res. 2004 Apr 1;64(7):2343-6
references.pmid: 15059883
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: Clin Cancer Res. 2004 Mar 1;10(5):1706-16
references.pmid: 15014023
references.citation: Eur J Cancer. 1999 Aug;35(8):1194-201
references.pmid: 10615229
references.citation: Curr Med Chem. 2006;13(16):1845-57
references.pmid: 16842197
references.citation: J Clin Oncol. 2000 Feb;18(4):724-33
references.pmid: 10673513
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Curr Opin Mol Ther. 2004 Jun;6(3):337-43
references.pmid: 15264437
references.citation: J Clin Oncol. 2001 Feb 1;19(3):851-6
references.pmid: 11157039
references.citation: Breast Cancer Res Treat. 2011 Dec;130(3):855-61
references.pmid: 21874312
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: J Clin Oncol. 2005 Feb 1;23(4):792-9
references.pmid: 15681523
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1993-9
references.pmid: 18421051